FPI-2068 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase I drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the FPI-2068 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FPI-2068 is under development for the treatment of metastatic solid tumor, colorectal cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma and non-small cell lung cancer. It comprises targeting antibody fused with actinium 225 radioisotope through fast clear linker. The drug candidate is a bispecific antibody. It acts by targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met). It is administered through intravenous route.
Fusion Pharmaceuticals overview
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company which develops targeted alpha-particle radio therapeutics for the treatment of cancers. It offers pipeline products such as FPI-1434, FPI-2059 and FPI-1966. The company’s pipeline products treat multiple cancers like head and neck bladder cancer, colorectal cancer and gastric cancers. It aslo include mono therapy and combination therapy. Fusion Pharmaceuticals carters its products under brand Keytruda. It has its operations in the US and Canada. Fusion Pharmaceuticals is headquartered in Hamilton, Ontario, Canada.
For a complete picture of FPI-2068’s drug-specific PTSR and LoA scores, buy the report here.